WO2011070948A1 - 精製ヒアルロン酸類の製造方法 - Google Patents
精製ヒアルロン酸類の製造方法 Download PDFInfo
- Publication number
- WO2011070948A1 WO2011070948A1 PCT/JP2010/071437 JP2010071437W WO2011070948A1 WO 2011070948 A1 WO2011070948 A1 WO 2011070948A1 JP 2010071437 W JP2010071437 W JP 2010071437W WO 2011070948 A1 WO2011070948 A1 WO 2011070948A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- purified
- molecular weight
- suspension
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
Definitions
- the present invention relates to a method for producing purified hyaluronic acid.
- Hyaluronic acid is widely distributed in living tissues such as chicken crown, umbilical cord, skin, cartilage, vitreous body, and joint fluid, and is widely used as a component of cosmetics, pharmaceuticals, and foods, for example.
- attempts have been made to use chemically modified hyaluronic acid and low molecular weight hyaluronic acid as components of cosmetics, pharmaceuticals, and foods.
- International Publication No. WO / 2008/133267 describes cationized hyaluronic acid and a method for producing the same.
- Japanese Patent Publication No. 5-77681 discloses a method for reducing the molecular weight of hyaluronic acid.
- Japanese Patent Publication No. 5-77681 discloses a method in which hyaluronic acid is decomposed in an acidic aqueous solution, ethanol is added to precipitate hyaluronic acid, and each filtered precipitate is purified by washing with ethanol. ing.
- this method since the recovery rate of hyaluronic acid is low, a more efficient production method is demanded for low molecular weight hyaluronic acid.
- the present invention provides a method for producing purified hyaluronic acid having a high recovery rate and capable of obtaining low-molecular purified hyaluronic acid.
- a method for producing purified hyaluronic acids includes: Adding a water-soluble organic solvent to a solution containing hyaluronic acid having an average molecular weight of 400 to 100,000 and having a pH of 3 or lower to obtain a suspension; Adjusting the suspension to pH 3.5-8 to precipitate purified hyaluronic acids; including.
- the solution before adding the water-soluble organic solvent may have a pH of 2 or less.
- a step of precipitating purified hyaluronic acid by adjusting the pH to 3.5 to 8 low-molecular purified hyaluronic acid can be obtained at a high recovery rate.
- % means “mass%” and “part” means “part by mass”.
- a method for producing purified hyaluronic acids according to the present embodiment comprises adding a water-soluble organic solvent to a solution containing hyaluronic acids having an average molecular weight of 400 to 100,000 and having a pH of 3 or less, and And obtaining the purified hyaluronic acid by adjusting the suspension to pH 3.5-8.
- the method for producing purified hyaluronic acid according to this embodiment can be performed after the step of treating the hyaluronic acid solution. Thereby, purified hyaluronic acids can be separated from other components in the treatment liquid by precipitation.
- the process of treating the hyaluronic acid solution includes, for example, an extraction process of hyaluronic acid and / or a salt thereof (for example, extraction from a natural product), a production process of hyaluronic acid and / or a salt thereof (for example, culture, chemical synthesis, enzyme) Synthesis), low molecular weight process of hyaluronic acid and / or salt thereof (eg, acid treatment, basic treatment, enzyme (eg, hyaluronidase) treatment, high pressure treatment, high temperature treatment, mechanical shearing treatment, electron beam irradiation treatment), hyaluron Examples thereof include a chemical modification step of an acid and / or a salt thereof (for example, chemical modification of a functional group contained in hyaluronic acid and / or a salt thereof).
- an extraction process of hyaluronic acid and / or a salt thereof for example, extraction from a natural product
- the step of treating hyaluronic acid with acid is 3 or less, considering the workability, the step of treating hyaluronic acid with acid Is preferred.
- the method for producing purified hyaluronic acid according to the present embodiment may be performed for the purpose of reducing impurities mixed in hyaluronic acid and / or a salt thereof.
- purified hyaluronic acids refers to those having a hyaluronic acid content of 90% or more (preferably 93% or more, more preferably 95% or more).
- content of hyaluronic acid is a value calculated from a glucuronic acid quantitative value measured by a carbazole sulfate method described later.
- the average molecular weight of the purified hyaluronic acid is preferably 400 to 100,000, more preferably 400 to 50,000, and still more preferably 400 to 10,000.
- the recovery rate of purified hyaluronic acid is high, and the purity of the purified hyaluronic acid can be increased by a simple method.
- the raw material in the method for producing purified hyaluronic acid according to the present embodiment is hyaluronic acid having an average molecular weight of preferably 400 to 100,000 (more preferably 400 to 50,000, more preferably 400 to 10,000).
- the “raw material” means hyaluronic acids that are targets of the method for producing purified hyaluronic acids according to the present embodiment. Therefore, after carrying out the step of treating the hyaluronic acid solution, when carrying out the method for producing purified hyaluronic acid according to the present embodiment, the average molecular weight of the raw material is, for example, after the step of treating the hyaluronic acid solution It means the average molecular weight of hyaluronic acids.
- the average molecular weight of the hyaluronic acid before the lowering of the molecular weight may be larger than 100,000 (for example, 4 to 3 million).
- the average molecular weight of hyaluronic acid as a raw material exceeds 100,000, it may gel when a water-soluble organic solvent is added to a solution adjusted to pH 3 or lower, and may not be separated into a suspension phase and a supernatant phase.
- hyaluronic acid refers to a polysaccharide having one or more repeating structural units composed of disaccharides of glucuronic acid and N-acetylglucosamine.
- hyaluronic acids is a concept including hyaluronic acid and hyaluronic acid derivatives and salts thereof.
- the “hyaluronic acid derivative” is a compound in which a functional group (for example, a hydroxyl group, a carboxyl group, an amide group) contained in hyaluronic acid is modified, such as cationized hyaluronic acid, acylated hyaluronic acid, Examples include acetylated hyaluronic acid.
- the “hyaluronic acid salt or hyaluronic acid derivative salt” is not particularly limited, but is preferably a food or pharmaceutically acceptable salt, for example, sodium salt, potassium salt, calcium salt, zinc salt, A magnesium salt, an ammonium salt, etc. are mentioned.
- Hyaluronic acid is basically a disaccharide or more containing at least one disaccharide unit in which the 1-position of ⁇ -D-glucuronic acid and the 3-position of ⁇ -DN-acetyl-glucosamine are bonded, and ⁇ It is basically composed of -D-glucuronic acid and ⁇ -DN-acetyl-glucosamine, and is a combination of a plurality of disaccharide units.
- the sugar may be an unsaturated sugar, and examples of the unsaturated sugar include non-reducing terminal sugars, usually those having unsaturated carbon atoms between positions 4 and 5 of glucuronic acid.
- the raw material hyaluronic acid and / or salt thereof may be extracted from natural products such as animals (for example, biological tissues such as chicken crown, umbilical cord, skin, joint fluid, etc.), or microorganisms or animal cells are cultured. (Eg, a fermentation method using Streptococcus bacteria), a chemically or enzymatically synthesized product, and the like can be used.
- animals for example, biological tissues such as chicken crown, umbilical cord, skin, joint fluid, etc.
- microorganisms or animal cells are cultured.
- a fermentation method using Streptococcus bacteria a chemically or enzymatically synthesized product, and the like can be used.
- the average molecular weight of (purified) hyaluronic acid is a value measured by the following method.
- the specific viscosity is measured by (Equation (1)), and the reduced viscosity at each concentration is calculated (Equation (2)).
- a graph is drawn with the reduced viscosity on the vertical axis and the concentration (g / 100 mL) of the product converted to dry matter on the horizontal axis, and the intrinsic viscosity is determined from the intersection of the straight line connecting the points and the vertical axis.
- the intrinsic viscosity determined here is substituted into Laurent's formula (formula (3)) to calculate the average molecular weight (Torvard C Laurent, Marion Ryan, and Adolph Pietruszkiewicz, “Fractionation of hyaluronic Acid”, Biochemina et Biophysica Acta.
- Hyaluronic acid content (Purified) In hyaluronic acid, the hyaluronic acid content is an indicator of the purity of (purified) hyaluronic acid. The higher the hyaluronic acid content, I can say that.
- the content of hyaluronic acid in (purified) hyaluronic acid is a value calculated from a glucuronic acid quantitative value measured by a carbazole sulfate method (for example, Japanese Pharmacopoeia).
- an aqueous solution of hyaluronic acid is added and mixed in a sodium borate / sulfuric acid solution, the hyaluronic acid is decomposed by heating, cooled, mixed with a carbazole / ethanol solution, heated and left to cool.
- This is a method for measuring absorbance (530 nm).
- a calibration curve is prepared using D-glucuronolactone treated in the same manner, and a D-glucuronolactone conversion value is calculated, and then multiplied by 1.102 to obtain a glucuronic acid quantitative value.
- the obtained glucuronic acid quantitative value is multiplied by (molecular weight of hyaluronic acid / molecular weight of glucuronic acid) to calculate the content of hyaluronic acid.
- Step of Obtaining Suspension In the method for producing purified hyaluronic acid according to this embodiment, a water-soluble organic solvent is added to a solution having a pH of 3 or less containing hyaluronic acid having an average molecular weight of 100,000 or less as a raw material. A turbid liquid is obtained.
- the “suspension” is a mixture in which solid fine particles are dispersed in a liquid.
- the suspension may be in a state where the solid is dispersed in the liquid and the liquid is cloudy, or may be separated into a suspension phase and a supernatant phase.
- the suspension is preferably separated into a suspension phase and a supernatant phase in that purified hyaluronic acids are likely to precipitate in a later step.
- the solvent of the solution containing hyaluronic acid as a raw material is water.
- the solution containing hyaluronic acid as a raw material may contain 2% or less (preferably 1% or less) of an inorganic salt such as sodium chloride, more preferably the concentration of the inorganic salt in the solution is less than 1%. is there.
- the concentration of hyaluronic acid is not particularly limited, but is preferably 0.1 to 30% and more preferably 1 to 10% from the viewpoint of increasing the recovery efficiency.
- the water-soluble organic solvent is added at least in an amount necessary for the solution to change into the suspension.
- the water-soluble organic solvent include alcohol solvents such as methanol, ethanol, 1-propanol, and 2-propanol, ketone solvents such as acetone and methyl ethyl ketone, tetrahydrofuran, acetonitrile, and the like. Can be used in combination. Of these, ethanol is preferred.
- the amount of the water-soluble organic solvent added is 1 part or more, preferably 1.5 to 50 parts, more preferably 1.5 to 20 parts with respect to 1 part of the solution containing hyaluronic acids. In this case, when the addition amount of the water-soluble organic solvent is less than 1 part with respect to 1 part of the solution containing hyaluronic acid, suspension is hardly generated.
- the solution before adding the water-soluble organic solvent is pH 3 or less, preferably pH 0.1 to 2.5, more preferably pH 0.1 to 2. If the pH of the solution before the addition of the water-soluble organic solvent exceeds 3, suspension is unlikely to occur even if the water-soluble organic solvent is added, and even if the pH of the solution is adjusted to 3.5 to 8 in the subsequent step. Purified hyaluronic acids are difficult to precipitate. In addition, if the pH of the solution before the addition of the water-soluble organic solvent is too low, a large amount of salt is produced when the pH of the solution is adjusted to 3.5 to 8 in the subsequent step, which may not be preferable. .
- the suspension is adjusted to pH 3.5 to 8 to precipitate purified hyaluronic acids.
- the pH of the suspension is out of the range of 3.5 to 8, it becomes difficult for the purified hyaluronic acid to precipitate.
- the suspension is preferably adjusted to pH 4 to 7 and more preferably adjusted to pH 4 to 6 in that a higher recovery rate can be achieved.
- test Method the average molecular weight of (purified) hyaluronic acid was measured by the method described in the above embodiment.
- the content of (purified) hyaluronic acid was calculated from the glucuronic acid quantitative value measured by the carbazole sulfate method.
- Example 1 Hydrochloric acid was added to 2 L of water to adjust the pH to 0.3 and warmed to 70 ° C. After reaching 70 ° C., 100 g of hyaluronic acid (average molecular weight 300,000, manufactured by QP Corporation) was added, and acid decomposition was performed at 70 ° C. for 2 hours. Thereafter, the reaction solution was cooled to room temperature, and 5 L of ethanol was added little by little to separate hyaluronic acid into a suspension phase and a supernatant phase.
- hyaluronic acid average molecular weight 300,000, manufactured by QP Corporation
- the pH was adjusted to 5.0 with sodium hydroxide to precipitate hyaluronic acid, and the precipitate was collected by filtration and washed with 500 mL of 80% (v / v) ethanol three times.
- the obtained precipitate was vacuum-dried at 60 ° C. to obtain purified hyaluronic acid.
- the average molecular weight of the purified hyaluronic acid obtained in Example 1 was 8,000, and the hyaluronic acid content was 95.4%. Note that the pH of the treatment solution before addition of ethanol was 0.3.
- Example 2 5.0 g of hyaluronic acid (average molecular weight 3,000, manufactured by QP Corporation) having a hyaluronic acid content of 91.1% was dissolved in 500 mL of water and adjusted to pH 1.0 with hydrochloric acid. Subsequently, 10 L of ethanol was slowly added with stirring to separate the hyaluronic acid into a suspension phase and a supernatant phase. Subsequently, the pH was adjusted to 5.0 with sodium hydroxide to precipitate hyaluronic acid, and the precipitate was collected by filtration and washed with 100 mL of 80% (v / v) ethanol three times. The obtained precipitate was vacuum-dried at 60 ° C. to obtain purified hyaluronic acid.
- hyaluronic acid average molecular weight 3,000, manufactured by QP Corporation
- the average molecular weight of the purified hyaluronic acid obtained in Example 2 was 3,000, and the hyaluronic acid content was 97.1%.
- Example 2 purification was performed in the same manner as in Example 2 except that the average molecular weight of hyaluronic acid used as a raw material, the pH of the treatment liquid before addition of ethanol, and the pH of the treatment liquid before precipitation were changed to those shown in Table 1.
- Hyaluronic acid No. 1-18, purified hyaluronic acid of Example 2 was No. 3 was produced.
- pH adjustment of the process liquid was performed using hydrochloric acid or sodium hydroxide.
- the hyaluronic acid content of purified hyaluronic acids 15 to 17 was 95% or more, and the average molecular weight was the same as that of the raw material hyaluronic acid.
- A After adding a water-soluble organic solvent, it was separated into a suspension phase and a supernatant phase, and precipitated after pH adjustment.
- B1 After the addition of the water-soluble organic solvent, it was separated into a suspension phase and a supernatant phase, and although it was slightly difficult to precipitate after pH adjustment, it was not problematic.
- C1 After addition of the water-soluble organic solvent, it was not separated into a suspension phase and a supernatant phase, and did not precipitate even after pH adjustment.
- B2 After the addition of the water-soluble organic solvent, the suspension phase and the supernatant phase were separated, but the solution was slightly gelled and slightly precipitated after pH adjustment, but was not problematic.
- C2 After addition of the water-soluble organic solvent, the suspension phase and the supernatant phase were not separated, and the solution was gelled and did not precipitate even after pH adjustment.
- C3 The suspension phase and the supernatant phase were separated immediately after addition of the water-soluble organic solvent, but did not precipitate after pH adjustment.
- Example 3 In the method for producing purified hyaluronic acid of Example 1, purified hyaluronic acid was produced in the same manner as in Example 1 except that ethanol added after cooling the reaction solution was changed to acetone.
- the average molecular weight of the purified hyaluronic acid obtained in Example 3 was 8,000, and the hyaluronic acid content was 96.0%.
- Example 4 In the method for producing purified hyaluronic acid of Example 2, purified hyaluronic acid was produced in the same manner as in Example 2 except that the water for dissolving hyaluronic acid used as a raw material was changed to 1% saline.
- the average molecular weight of the purified hyaluronic acid obtained in Example 4 was 3,000, and the hyaluronic acid content was 94.0%.
- Example 5 In the method for producing purified hyaluronic acid of Example 2, purified hyaluronic acid was produced in the same manner as in Example 2 except that the water for dissolving hyaluronic acid used as a raw material was changed to 2% saline. In Examples 1 to 3, the salt concentration of the treatment solution before the addition of ethanol is less than 1%.
- the average molecular weight of the purified hyaluronic acid obtained in Example 5 was 3,000, and the hyaluronic acid content was 91.9%.
- Example 6 In a 1 L beaker, 20 g of sodium hyaluronate (manufactured by QP Corporation, average molecular weight 8000), 20 mL of 5% sodium hydroxide, 180 mL of water, and glycidyltrimethylammonium chloride (GTA (active ingredient about 80%, moisture about 20%)) 30 mL was added, and the mixture was reacted at 40 ° C. for 1 hour while stirring with a stir bar.
- GTA active ingredient about 80%, moisture about 20%
- the pH was adjusted to 1.0 with hydrochloric acid. Subsequently, 800 mL of ethanol was slowly added with stirring to separate the hyaluronic acid into a suspension phase and a supernatant phase. Subsequently, the pH was adjusted to 4.0 with sodium hydroxide to precipitate hyaluronic acid, and the precipitate was collected by filtration and washed with 500 mL of 80% ethanol three times. The resulting precipitate was vacuum dried at 60 ° C. to obtain purified cationized hyaluronic acid.
- the average molecular weight of the purified cationized hyaluronic acid obtained in Example 6 was 6,000, and the content of cationized hyaluronic acid was 95.6%.
- the present invention includes configurations that are substantially the same as the configurations described in the embodiments (for example, configurations that have the same functions, methods, and results, or configurations that have the same purposes and results).
- the invention includes a configuration in which a non-essential part of the configuration described in the embodiment is replaced.
- the present invention includes a configuration that achieves the same effect as the configuration described in the embodiment or a configuration that can achieve the same object.
- the invention includes a configuration in which a known technique is added to the configuration described in the embodiment.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Dermatology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
平均分子量が400~10万であるヒアルロン酸類を含むpH3以下の溶液に水溶性有機溶媒を添加して、懸濁液を得る工程と、
前記懸濁液をpH3.5~8に調整して、精製ヒアルロン酸類を沈殿させる工程と、
を含む。
本実施形態に係る精製ヒアルロン酸類の製造方法は、平均分子量が400~10万であるヒアルロン酸類を含むpH3以下の溶液に水溶性有機溶媒を添加して、懸濁液を得る工程と、懸濁液をpH3.5~8に調整して、精製ヒアルロン酸類を沈殿させる工程と、を含む。
本実施形態に係る精製ヒアルロン酸類の製造方法における原料は、平均分子量が好ましくは400~10万(より好ましくは400~5万、さらに好ましくは400~1万)であるヒアルロン酸類である。ここで、「原料」とは、本実施形態に係る精製ヒアルロン酸類の製造方法の対象となるヒアルロン酸類を意味する。したがって、ヒアルロン酸溶液を処理する工程を行った後に、本実施形態に係る精製ヒアルロン酸類の製造方法を実施する場合、原料の平均分子量は、例えば、ヒアルロン酸溶液を処理する工程を行った後のヒアルロン酸類の平均分子量を意味する。よって、例えば、ヒアルロン酸溶液を処理する工程が低分子化である場合、低分子化する前のヒアルロン酸類の平均分子量は10万より大きくてもよい(例えば400~300万)。
本発明において、(精製)ヒアルロン酸類の平均分子量は、以下の方法にて測定された値である。
(式1)
比粘度 = {試料溶液の所要流下秒数)/(0.2mol/L塩化ナトリウム溶液の所要流下秒数)}-1
(式2)
還元粘度(dL/g)= 比粘度/(本品の換算した乾燥物に対する濃度g/100mL))
(式3)
極限粘度(dL/g)=3.6×10-4M0.78
M:平均分子量
(精製)ヒアルロン酸類において、ヒアルロン酸類の含有量は、(精製)ヒアルロン酸類の純度の指標であり、ヒアルロン酸類の含有量が多いほど、(精製)ヒアルロン酸類の純度が高いといえる。
本実施形態に係る精製ヒアルロン酸類の製造方法では、原料である平均分子量が10万以下であるヒアルロン酸類を含むpH3以下の溶液に水溶性有機溶媒を添加することにより、懸濁液を得る。
本実施形態に係る精製ヒアルロン酸類の製造方法において、懸濁液をpH3.5~8に調整して、精製ヒアルロン酸類を沈殿させる。この場合、懸濁液のpHが3.5~8の範囲を外れると、精製ヒアルロン酸類が沈殿するのが困難になる。また、より高い回収率を達成できる点で、懸濁液をpH4~7に調整するのが好ましく、pH4~6に調整するのがより好ましい。
以下、実施例によって本発明をさらに詳細に説明するが、本発明は実施例に限定されない。
本実施例において、(精製)ヒアルロン酸類の平均分子量は、上述の実施形態で説明された方法で測定された。また、(精製)ヒアルロン酸類の含有量は、カルバゾール硫酸法によって測定されたグルクロン酸定量値から算出された。
水2Lに塩酸を加えて、pHを0.3に調整し、70℃まで加温した。70℃達温後、ヒアルロン酸(平均分子量30万、キユーピー株式会社製)100gを投入し、70℃で2時間酸分解させた。その後、反応液を常温まで冷却し、エタノール5Lを少しずつ加えてヒアルロン酸を懸濁相と上澄み相に分離させた。次いで、水酸化ナトリウムでpHを5.0に調整し、ヒアルロン酸を沈殿させ、沈殿物をろ過にて回収し、80%(v/v)エタノール500mLで3回洗浄した。得られた沈殿物を60℃で真空乾燥させて、精製ヒアルロン酸を得た。
ヒアルロン酸含有量が91.1%であるヒアルロン酸(平均分子量3,000、キユーピー株式会社製)5.0gを水500mLに溶解させ、塩酸にてpH1.0に調整した。次いで、エタノール10Lを撹拌しながらゆっくり添加し、ヒアルロン酸を懸濁相と上澄み相に分離させた。次いで、水酸化ナトリウムでpHを5.0に調整し、ヒアルロン酸を沈殿させ、沈殿物をろ過にて回収し、80%(v/v)エタノール100mLで3回洗浄した。得られた沈殿物を60℃で真空乾燥させて、精製ヒアルロン酸を得た。
実施例2において、原料として用いるヒアルロン酸の平均分子量およびエタノール添加前の処理液のpH、沈殿前の処理液のpHを表1に示すものにした以外は、実施例2と同様の方法で精製ヒアルロン酸(No.1~18、実施例2の精製ヒアルロン酸はNo.3)を製した。なお、処理液のpH調整は、塩酸または水酸化ナトリウムを用いて行った。また、沈殿が生じたNo.1~5、No.8~12、No.15~17の精製ヒアルロン酸のヒアルロン酸含有量はいずれも95%以上であり、平均分子量は原料ヒアルロン酸のそれと変わらないものであった。
A :水溶性有機溶媒添加後に懸濁相と上澄み相に分離し、pH調整後に沈殿した。
B1:水溶性有機溶媒添加後に懸濁相と上澄み相に分離し、pH調整後にやや沈殿し難かったが問題とならない程度であった。
C1:水溶性有機溶媒添加後に懸濁相と上澄み相に分離せず、pH調整後も沈殿しなかった。
B2:水溶性有機溶媒添加後に懸濁相と上澄み相に分離したが、溶液がややゲル化し、pH調整後にやや沈殿し難かったが問題とならない程度であった。
C2:水溶性有機溶媒添加後に懸濁相と上澄み相に分離せず、溶液がゲル化し、pH調整後も沈殿しなかった。
C3:水溶性有機溶媒添加直後に懸濁相と上澄み相に分離したが、pH調整後に沈殿しなかった。
実施例1の精製ヒアルロン酸の製造方法において、反応液を冷却した後に加えたエタノールをアセトンに変更した以外は実施例1と同様の方法で精製ヒアルロン酸を製した。
実施例2の精製ヒアルロン酸の製造方法において、原料として用いるヒアルロン酸を溶解する水を1%食塩水に変更した以外は、実施例2と同様の方法で精製ヒアルロン酸を製した。
実施例2の精製ヒアルロン酸の製造方法において、原料として用いるヒアルロン酸を溶解する水を2%食塩水に変更した以外は、実施例2と同様の方法で精製ヒアルロン酸を製した。なお、実施例1~3でエタノール添加前の処理液の食塩濃度は1%未満である。
1L容ビーカーに、ヒアルロン酸ナトリウム(キユーピー株式会社製、平均分子量8000)20g、5%水酸化ナトリウム20mL、水180mL、およびグリシジルトリメチルアンモニウムクロリド(GTA(有効成分約80%、水分約20%))30mLを添加し、撹拌子を用いて撹拌しながら、40℃で1時間反応させた。
Claims (2)
- 平均分子量が400~10万であるヒアルロン酸類を含むpH3以下の溶液に水溶性有機溶媒を添加して、懸濁液を得る工程と、
前記懸濁液をpH3.5~8に調整して、精製ヒアルロン酸類を沈殿させる工程と、
を含む、精製ヒアルロン酸類の製造方法。 - 前記水溶性有機溶媒を添加する前の前記溶液がpH2以下である、請求項1記載の精製ヒアルロン酸類の製造方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011514955A JP4810628B2 (ja) | 2009-12-08 | 2010-12-01 | 精製ヒアルロン酸類の製造方法 |
CN201080055315.6A CN102648214B (zh) | 2009-12-08 | 2010-12-01 | 纯化透明质酸类的制造方法 |
KR1020127017493A KR101450983B1 (ko) | 2009-12-08 | 2010-12-01 | 정제 히알루론산류의 제조 방법 |
US13/388,010 US8829180B2 (en) | 2009-12-08 | 2010-12-01 | Method of purifying a low molecular weight hyaluronic acid or cationized hyaluronic acid via precipitation from aqueous solution by addition of alcohol or acetone followed by ph adjustment |
EP10835870.6A EP2511302B1 (en) | 2009-12-08 | 2010-12-01 | Method for manufacturing purified hyaluronic acids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009278259 | 2009-12-08 | ||
JP2009-278259 | 2009-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011070948A1 true WO2011070948A1 (ja) | 2011-06-16 |
Family
ID=44145493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/071437 WO2011070948A1 (ja) | 2009-12-08 | 2010-12-01 | 精製ヒアルロン酸類の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8829180B2 (ja) |
EP (1) | EP2511302B1 (ja) |
JP (1) | JP4810628B2 (ja) |
KR (1) | KR101450983B1 (ja) |
CN (1) | CN102648214B (ja) |
TW (1) | TWI510501B (ja) |
WO (1) | WO2011070948A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015108029A1 (ja) * | 2014-01-14 | 2015-07-23 | キユーピー株式会社 | ヒアルロン酸および/またはその塩およびその製造方法、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 |
JP2016108344A (ja) * | 2014-12-08 | 2016-06-20 | ワミレスコスメティックス株式会社 | 低分子量カチオン化ヒアルロン酸を含有する化粧料 |
JP2017025157A (ja) * | 2015-07-17 | 2017-02-02 | キユーピー株式会社 | ヒアルロン酸および/またはその塩、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011129370A1 (ja) * | 2010-04-14 | 2011-10-20 | キユーピー株式会社 | ヒアルロン酸金属塩の製造方法、ヒアルロン酸金属塩を含む化粧品の製造方法、ならびにヒアルロン酸亜鉛およびその製造方法 |
JP6865980B2 (ja) * | 2017-04-07 | 2021-04-28 | ユーレー カンパニー リミテッドYoureh Co.,Ltd. | 低分子量ヒアルロン酸の製造方法 |
CN109206537B (zh) * | 2018-10-10 | 2021-04-09 | 华熙生物科技股份有限公司 | 一种乙酰化透明质酸钠的制备方法及其应用 |
CN114133465B (zh) * | 2020-09-03 | 2023-03-21 | 山东华熙海御生物医药有限公司 | 一种透明质酸钾的制备方法及所得产品和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357602A (ja) * | 1986-08-29 | 1988-03-12 | Q P Corp | 低分子ヒアルロン酸の製法 |
JPH05255045A (ja) * | 1992-03-13 | 1993-10-05 | Kanebo Ltd | 養毛料 |
JP2006036666A (ja) * | 2004-07-26 | 2006-02-09 | Japan Science & Technology Agency | ケモカイン受容体ccr10の発現誘導剤 |
JP2006265287A (ja) * | 2005-03-22 | 2006-10-05 | Q P Corp | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
JP2007186689A (ja) * | 2005-12-13 | 2007-07-26 | Shiseido Co Ltd | 低分子量ヒアルロン酸の製造方法 |
JP2008179710A (ja) * | 2007-01-25 | 2008-08-07 | Shiseido Co Ltd | 低分子量ヒアルロン酸の製造方法 |
WO2008133267A1 (ja) | 2007-04-24 | 2008-11-06 | Q.P. Corporation | カチオン化ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを用いた毛髪改質剤、キューティクル修復剤、皮膚改質剤および化粧料 |
JP2009155486A (ja) * | 2007-12-27 | 2009-07-16 | Kikkoman Corp | 低分子化ヒアルロン酸とその製造法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2587268B2 (ja) | 1988-04-18 | 1997-03-05 | チッソ株式会社 | 低粘度ヒアルロン酸又はその塩の製造方法 |
US6630457B1 (en) * | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
TW200643033A (en) * | 2005-03-08 | 2006-12-16 | Chugai Pharmaceutical Co Ltd | Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue |
US7879818B2 (en) * | 2005-12-23 | 2011-02-01 | Janos Borbely | Hyaluronic acid-based cross-linked nanoparticles |
JP5077681B2 (ja) | 2008-03-21 | 2012-11-21 | マツダ株式会社 | 車両のステアリングロック装置 |
-
2010
- 2010-12-01 WO PCT/JP2010/071437 patent/WO2011070948A1/ja active Application Filing
- 2010-12-01 JP JP2011514955A patent/JP4810628B2/ja active Active
- 2010-12-01 US US13/388,010 patent/US8829180B2/en active Active
- 2010-12-01 TW TW099141791A patent/TWI510501B/zh active
- 2010-12-01 CN CN201080055315.6A patent/CN102648214B/zh active Active
- 2010-12-01 EP EP10835870.6A patent/EP2511302B1/en active Active
- 2010-12-01 KR KR1020127017493A patent/KR101450983B1/ko active IP Right Grant
-
2014
- 2014-07-31 US US14/448,317 patent/US20140343269A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357602A (ja) * | 1986-08-29 | 1988-03-12 | Q P Corp | 低分子ヒアルロン酸の製法 |
JPH0577681B2 (ja) | 1986-08-29 | 1993-10-27 | Q P Corp | |
JPH05255045A (ja) * | 1992-03-13 | 1993-10-05 | Kanebo Ltd | 養毛料 |
JP2006036666A (ja) * | 2004-07-26 | 2006-02-09 | Japan Science & Technology Agency | ケモカイン受容体ccr10の発現誘導剤 |
JP2006265287A (ja) * | 2005-03-22 | 2006-10-05 | Q P Corp | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
JP2007186689A (ja) * | 2005-12-13 | 2007-07-26 | Shiseido Co Ltd | 低分子量ヒアルロン酸の製造方法 |
JP2008179710A (ja) * | 2007-01-25 | 2008-08-07 | Shiseido Co Ltd | 低分子量ヒアルロン酸の製造方法 |
WO2008133267A1 (ja) | 2007-04-24 | 2008-11-06 | Q.P. Corporation | カチオン化ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを用いた毛髪改質剤、キューティクル修復剤、皮膚改質剤および化粧料 |
JP2009155486A (ja) * | 2007-12-27 | 2009-07-16 | Kikkoman Corp | 低分子化ヒアルロン酸とその製造法 |
Non-Patent Citations (4)
Title |
---|
"Japanese Pharmacopoeia" |
CHIKAKO YOMOTA: "Evaluation of Molecular Weights of Hyaluronate Preparations by Multi-Angle Laser Light Scattering", BULL.NATL.INST.HEALTH SCI., vol. 121, 2003, pages 030 - 033 |
See also references of EP2511302A4 |
TORVARD C LAURENT; MARION RYAN; ADOLPH PIETRUSZKIEWICZ: "Fractionation of hyaluronic Acid", BIOCHEMINA ET BIOPHYSICA ACTA., vol. 42, 1960, pages 476 - 485, XP023382851, DOI: doi:10.1016/0006-3002(60)90826-X |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015108029A1 (ja) * | 2014-01-14 | 2015-07-23 | キユーピー株式会社 | ヒアルロン酸および/またはその塩およびその製造方法、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 |
JP5824599B1 (ja) * | 2014-01-14 | 2015-11-25 | キユーピー株式会社 | ヒアルロン酸および/またはその塩の製造方法 |
JP2016108344A (ja) * | 2014-12-08 | 2016-06-20 | ワミレスコスメティックス株式会社 | 低分子量カチオン化ヒアルロン酸を含有する化粧料 |
JP2017025157A (ja) * | 2015-07-17 | 2017-02-02 | キユーピー株式会社 | ヒアルロン酸および/またはその塩、ならびに、該ヒアルロン酸および/またはその塩を含む食品、化粧料、および医薬品 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2011070948A1 (ja) | 2013-04-22 |
KR20120089772A (ko) | 2012-08-13 |
KR101450983B1 (ko) | 2014-10-15 |
TWI510501B (zh) | 2015-12-01 |
EP2511302B1 (en) | 2014-11-12 |
US20120130063A1 (en) | 2012-05-24 |
EP2511302A1 (en) | 2012-10-17 |
US20140343269A1 (en) | 2014-11-20 |
EP2511302A4 (en) | 2013-10-02 |
US8829180B2 (en) | 2014-09-09 |
JP4810628B2 (ja) | 2011-11-09 |
CN102648214B (zh) | 2015-02-18 |
TW201136947A (en) | 2011-11-01 |
CN102648214A (zh) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4810628B2 (ja) | 精製ヒアルロン酸類の製造方法 | |
EP1270599B1 (en) | Salmon-origin chondroitin sulfate | |
JP4613008B2 (ja) | キト−オリゴマーを含む医薬組成物 | |
CN114133419B (zh) | 一种低分子量乙酰化透明质酸盐及其制备方法和应用 | |
JP2587268B2 (ja) | 低粘度ヒアルロン酸又はその塩の製造方法 | |
CN106188341B (zh) | 肝素钠下脚料制备高纯度硫酸皮肤素工艺 | |
JP2005501930A (ja) | 哺乳動物の外科的若しくは治療的な処置方法、又は診断方法に使用、特に血漿増量剤に使用をする高度分枝アミロペクチン | |
JP5053512B2 (ja) | 非常に大きい硫酸化度を持つk5多糖体のエピマー化誘導体 | |
KR101788536B1 (ko) | 상어유사 콘드로이틴 설페이트 및 이의 제조방법 | |
KR101858733B1 (ko) | 초저분자량 히알루론산의 제조방법 | |
JP2011084588A (ja) | ヒアルロン酸および/またはその塩からなる粉末 | |
JP4719878B2 (ja) | アオヤギ由来のコンドロイチン硫酸 | |
Ibram | Studies on chitosan, chitin and chitooligosaccharides and their biomedical properties | |
US9718947B2 (en) | Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof | |
JP5758878B2 (ja) | ヒアルロン酸の精製方法 | |
JP2011079748A (ja) | ヒアルロン酸および/またはその塩を含有するハードカプセルおよび錠剤 | |
JP2011063526A (ja) | 経口用肌改善剤および肌改善用食品組成物 | |
CN110698522A (zh) | 一种软骨素奇数寡糖单体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080055315.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011514955 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10835870 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13388010 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010835870 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127017493 Country of ref document: KR Kind code of ref document: A |